Isosorbide Mononitrate Market Scope
Isosorbide mononitrate is a nitrate that dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump. Isosorbide mononitrate is used to prevent angina attacks. Isosorbide Mononitrate is a nitrate. It reduces the workload of the heart. As a result, the heart muscle does not need as much blood and oxygen supply.
The Isosorbide Mononitrate market study is segmented by Type (10 mg Tablet and 20 mg Tablet), by Application (Angina Pectoris and Others) and major geographies with country level break-up.
The market is fragmented with numerous players focusing on technique and quality of the product due to which the global Isosorbide Mononitrate market can witness an upsurge in the forecast period. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Isosorbide Mononitrate market throughout the predicted period.
Teva Pharmaceutical Industries Ltd (Israel), Merck Group (United States), Nesher Pharmaceuticals (United States), Taj pharmaceutical (India), AMRI India (India), Intas Pharmaceuticals (India), Sandoz (Germany), Shandong Fangming Pharmaceutical Group (China) and ReYoung Pharmaceutical (China) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Isosorbide Mononitrate market by Type, Application and Region.
On the basis of geography, the market of Isosorbide Mononitrate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In Sept 2018, Avet Pharmaceuticals Inc.announced the immediate availability of Isosorbide Mononitrate Extended-Release 30mg tablets. This launch adds to Avet’s robust portfolio of generic oral solid products and is an addition to Avet’s marketed Isosorbide Mononitrate ER 60mg tablets. Isosorbide Mononitrate is the AB-rated generic equivalent to the antianginal drug Imdur®. It is indicated for the prevention of angina pectoris due to coronary artery disease.
- Prevention of Angina Pectoris caused by Coronary Artery Disease
- Rising Number Patients Worldwide Related Chest Pain Problems
- Rising Demand from Emerging Economics such as India, China, and Others
- Increasing Number of Cholesterol, Heart Attack Related Patients
- Common Side Effects of Isosorbide Mononitrate Headache, Dizziness, Flushing, Orthostatic hypotension (sudden lowering of blood pressure on standing)
- Lack of Awareness Regarding the Benefit of Isosorbide Mononitrate
Key Target AudienceVenture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Isosorbide Mononitrate Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase